For the Urologist by the Urologist: Essential Concepts in Managing mCRPC
Goals
Case Study: Newly Diagnosed Low Volume Metastatic Disease
CHAARTED: Benefit of Docetaxel
Toxicity Grade 3 AE or Greater
Treating the Primary Tumor
Case Study, Continued
Abiraterone COU-AA-302 Trial
Enzalutamide PREVAIL Trial
Treatment Considerations: Use of Immunotherapy
Sipuleucel-T
Treatment Considerations: Abiraterone vs Enzalutamide
Case Study: mCRPC Progressing Through Second Generation Androgen Axis Inhibitors
Further Treatment Considerations
Emerging Biomarkers
Biomarkers: Mutations of DNA Repair and High Rate of Response to Olaparib
Cabazitaxel
Conclusions
Remaining Questions